CSL Limited Annual Report 2021/22 48 Our greatest opportunity to contribute to society is through the development of new therapies for serious unmet medical needs and through the continued supply of life-saving vaccines and plasma and protein-based therapies. From developing new, innovative therapies for diseases to enabling greater access to life-saving vaccines, protecting the safety and wellbeing of our patients and communities around the world sits at the center of our purpose as a business. This includes a commitment to a positive experience and the trust of our donors, who make vital therapies possible, and to continuous engagement with the stakeholders we depend upon to fulfill our promise. In addition to material topics featured, our strategic sustainability focus areas include: • strengthening societal health through access to our existing products and therapies and investment in innovation; • being trusted by donors through a focus on their experience and wellbeing, and their communities; and • enhancing our industry position as a patientfocussed and public health leader. Plasma donors CSL Plasma is one of the world’s largest collectors of human plasma and a leader in plasma collection. CSL Plasma’s 14,000 employees commit to excellence and innovation across the full cycle of plasma collection, including donor screening, the donation process, plasma testing and logistics, ensuring plasma is available for the manufacturing of life-saving therapies. Plasma donors continue to be the critical link to ensure tens of thousands of people can live normal, healthy lives. The company has strengthened and grown its footprint to support a positive donor experience and reliable plasma supply as patient demand has increased. Donor management and safe, compliant and efficient plasma collection remain integral to a quality supply of rawmaterial. More than 300 CSL Plasma centres provide the plasma that is the foundation of life-saving and life-enhancing therapies, as well as serving as a positive force in local communities, supporting donor wellbeing and the surrounding area. As one example, for a second year in a row, CSL Plasma provided vouchers to plasma donors in the U.S. to access influenza vaccines at no cost at a local pharmacy during the US autumn and winter seasons, when influenza is most likely to manifest and spread. CSL Plasma donor experience and profile The socio-demographic background of US CSL Plasma donors remains diverse. Based on self-reported survey data administered through the newly deployed CSL Plasma mobile app (1 Sept 2021 to 30 June 2022), CSL Plasma donors provided details on occupational status^: • 55% described themselves as working full-time. • 20% described themselves as unemployed, inclusive of full-time parents, donors who are not looking for work or the unemployed. • 15% described themselves as part-time. • 3% described themselves as students. • 7% described themselves as other (e.g. military, retired). Of those plasma donors surveyed, 95% are willing to donate again, and 91% of plasma donors are willing to refer a friend to donate plasma at their CSL Plasma centre.^ 95% of plasma donors are willing to donate again^ 91% of plasma donors are willing to refer a friend to donate plasma at their CSL Plasma centre^ 9 Social ^ Limited assurance by Ernst & Young. CSL Plasma updated post-donation survey questions in September 2021 to use a Likert response scale from a prior yes or no answer. Data is based on 2.9 million survey responses. The percentages for willing to donate and refer a friend are comprised of total number of respondents who selected the top two (4 and 5) of five numbers on the Likert scale. US$9.9 billion over the reporting period distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions* *Limited assurance by Ernst & Young.
RkJQdWJsaXNoZXIy MjE2NDg3